Publication
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerGastric Adenocarcinomacivic_curation1.00
- drugTrastuzumabcivic_curation1.00
- geneERBB2civic_curation1.00
- variantERBB2 Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 20728210
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERBB2 Amplification3 | ||||||||
| Trastuzumab | Gastric Adenocarcinoma | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID1499ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive (overexpression or amplification) advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and plati… (full text at CIViC) PMID 20728210 · Bang et al., 2010 · Open in CIViC | civic |
| 〃 | Gastric Adenocarcinoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID1022ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been co… (full text at CIViC) PMID 20728210 · Bang et al., 2010 · Open in CIViC | civic |
| Chemotherapy + TrastuzumabCombination | Gastroesophageal Junction Adenocarcinoma | Predictive | A | Supports Sensitivity Response | 5 | submitted | EID11256In this phase 3, open-label, randomized controlled trial, 594 patients (584 in the primary analysis) with HER2-positive amplification or overexpression gastric or gastroesophageal junction adenocarcin… (full text at CIViC) PMID 20728210 · Bang et al., 2010 · Open in CIViC | civic |
| ERBB2 Amplification + ERBB2 Overexpression1 | ||||||||
| Chemotherapy + TrastuzumabCombination | Malignant Gastric Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | submitted | EID11255In this phase 3, open-label, randomized controlled trial, 594 patients (584 in the primary analysis) with HER2-positive amplification or overexpression gastric or gastroesophageal junction adenocarcin… (full text at CIViC) PMID 20728210 · Bang et al., 2010 · Open in CIViC | civic |